Post-translational modification of SOX family proteins

Citation for published version:

Digital Object Identifier (DOI):
10.1016/j.semcancer.2019.09.009

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Version created as part of publication process; publisher's layout; not normally made publicly available

Published In:
seminars in cancer biology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Review

Post-translational modification of SOX family proteins: Key biochemical targets in cancer?

Charles A.C. Williams, Abdenour Soufi, Steven M. Pollard*

MRC Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, EH16 4UU, Edinburgh, United Kingdom

ARTICLE INFO

Keywords: SOX, Post-translational modification, Stem cell, Cancer, Transcription

ABSTRACT

Sox proteins are a family of lineage-associated transcription factors. They regulate expression of genes involved in control of self-renewal and multipotency in both developmental and adult stem cells. Overexpression of Sox proteins is frequently observed in many different human cancers. Despite their importance as therapeutic targets, Sox proteins are difficult to 'drug' using structure-based design. However, Sox protein localisation, activity and interaction partners are regulated by a plethora of post-translational modifications (PTMs), such as: phosphorylation, acetylation, sumoylation, methylation, and ubiquitylation. Here we review the various reported post-translational modifications of Sox proteins and their potential functional importance in guiding cell fate processes. The enzymes that regulate these PTMs could be useful targets for anti-cancer drug discovery.

1. Introduction

Within many tissues, undifferentiated multipotent stem and progenitor cells sustain the turnover of new cells during tissue homeostasis and repair. Developmental transcription factors (TFs) and their associated core transcriptional apparatus are key determinants of cell type identity. These orchestrate the balance between self-renewal and differentiation. In many types of cancer, these developmental TFs (e.g. HOX, FOX, SOX and bHLH proteins) become deregulated and drive “stemness,” enforcing an immature cellular phenotype and limiting possibilities for terminal cell differentiation [1]. Excellent reviews have discussed the diverse SOX protein functions across stem cells, development and cancer [2,3]. Here we focus our discussions on the function of SOX post-translational modifications (PTMs) and whether these could be critical targets for new anti-cancer drug discovery.

Developmental TFs often operate in a combinatorial manner, as 'co-operatives' and are often termed master regulatory transcription factors [4]. In many cancers changes in gene expression which underpin tumour growth, are driven by key oncogenic signalling TFs, such as: STAT, SMAD, TCF, ETS [5,6]; these are the transcriptional effectors of LIF, TGFBeta, Wnt and ERK pathways, respectively. Convergence of these oncogenic, or signalling TFs, with master developmental TFs likely occurs by their shared binding/co-localisation at key enhancers or superenhancers, which drives robust expression of cell type specific target genes [5]. This is why high-grade cancers typically have historical resemblance to the corresponding foetal tissue or regenerating tissue from the cell of origin. They exploit the molecular apparatus used by stem cells. Targeting cancer stem-cell-like identity could therefore be achieved by targeting the activity of these core TFs.

2. ‘Drugging’ transcription factors

There are ∼1600 TFs encoding genes in the human genome [7]. TFs form protein complexes that activate or repress transcription at specific target genes, by binding to regulatory sites in the genome. TFs typically have a modular design, with core DNA binding domains separate from effector domains (e.g. activation, repression or chromatin-interacting). Many also harbour non-structured domains, such as stretches of alanine, proline or glycine residues, and these confer an important functional role in supporting the formation of biophysically separated sub-nuclear domains, termed transcriptional condensates.

Disrupting these TFs, or their complexes, using small molecules has proven difficult due them targeting protein-protein interactions, with large, flat surface areas which do not offer druggable binding pockets. They have therefore been viewed as difficult to targets to 'drug' using classic structure-based design methods that have been so successful for targets with catalytic sites. Alternative strategies are therefore needed.

PTM is a dynamic, reversible process adapted to rapidly transmit signalling information. PTM dynamics are frequently centred on enzymes that catalyse the addition, removal and “reading” of these sites. In the last 10–20 years there has been great interest in targeting cancer signalling pathways, which often involve complex networks and
cascades of post-translation modifications (PTMs) [8]. Genetic disruption to these core cancer pathways (e.g. receptor tyrosine kinase signalling) is frequently observed across many human cancers. Therefore, the tools for studying and identifying new small molecule inhibitors are well established. Perhaps the most widely explored PTM is phosphorylation, which is catalysed by kinases and reversed by phosphatases [9].

PTMs can be broadly separated into 2 categories: chemical modifications (e.g. phosphorylation/methylation/acetylation) and small protein modifications (e.g. ubiquitylation/SUMOylation). Searching for post-translational modifications (PTMs) which might be critical for TF activity, might offer a wealth of new targets, as the associated enzymes could be amenable to inhibition. However, there remain extensive gaps in our knowledge. Below, we will focus discussion on how these modifications and associated interactions provide a novel target for cancer therapies. How do these PTMs arise? What is their key function? Can they be modulated using small molecules? SOX proteins are attracting particular attention, as their overexpression is a recurrent feature of the majority of human cancers (Fig. 1).
3. SOX proteins

The male sex determination gene SRY was the founding member of the SOX family (from which the family takes its name: Sex determining region Y (SRY)-related high-mobility group HMG-box) [11,12]. SOX proteins bind to the DNA sequence motif ATTGTT (or related sequences) through the three alpha helices within the HMG domains that form a L-shaped domain that interacts with the DNA minor groove [13,14]. This interaction is thought to trigger a conformational change, bending the DNA, and this may contribute to Sox function [15]. However, it is also the case that Sox factors have affinity to ‘pre-bent’ DNA that is present within nucleosomes – wrapped around the histone octamer – explaining their activity as pioneer factors (see pioneer factor discussion below).

The SOX transcription factor family comprises of over 20 members of which there are 11 subgroups categorised on the basis of their HMG box and associated domains (Fig. 2). These are classified into groups termed A-H, depending on the similarity of the HMG domains [3,16]. Sry, is the only member of the SoxA group [17]. The SoxB family is subdivided into two subgroups with similar HMG domains: SoxB1 and B2. SoxB1 members (Sox1, Sox2 and Sox3) have a transcriptional activation domain in their C-terminus whereas SoxB2 (Sox14, Sox21) have transcriptional repression domain in the C-terminus [18,19]. The SoxG protein, Sox15, is related to SoxB; however its molecular functions remain unclear [20]. SoxC/E/F are analogous to SoxB1 with N-terminal HMG domains and transcriptional activation domains; however, there are significant differences in protein sequences beyond these domains.

Notably, SoxE family (Sox8, Sox9 and Sox10) contain a N-terminal dimerisation domain which plays a role in remodelling chromatin [21–23]. SoxD have C-terminal HMG domains and N-terminal coiled-coil domains which mediate SoxD family dimerization and thereby preferential binding to pairs of DNA recognition sites [24]. These factors are also less stringent in DNA binding motifs resulting in putative SoxD binding sites at most promoters/regulatory regions [25]. Loosely related to SoxD is the SoxG protein, Sox30, which is the most divergent member, these Sox proteins contain the remnants of a coiled coil domain and a C-terminal HMG domain [26]. PTMs may therefore have specific effects on each SOX member based on their distinct protein domain architectures. For this review modified residues will be stated in the species variant (mm: mus musculus; hs: homo sapien) in which the study was conducted.

4. Consequences of SOX post-translation modifications

Sox protein PTMs have been reported across the spectrum of common modifications, including: phosphorylation, acetylation, methylation, SUMOylation, and ubiquitination (Fig. 3). These modifications represent druggable targets through targeting the enzymes that catalyse either their addition or removal. Many known PTMs have an annotated function; however, numerous proteomic mass spectrometry screens have revealed novel and functionally uncharacterised PTMs on Sox factors [27–34]. An increasingly long list of new PTMs has therefore emerged, and we do not know the identity or role of the associated enzyme. These provide many new avenues to investigate and will likely be corrupted in cancer. There are several strategies that have been uncovered in which SOX activity can be modulated (Fig. 4), and these are discussed below.

5. PTMs that modulate DNA binding properties

Critical to Sox protein function is its ability to bind sequence-specific sites in the genome. Either disrupting or promoting DNA interactions may therefore influence Sox activity and shift key targets, either oncogene or tumour suppressor. All 20 Sox factors interact with DNA through a highly positive binding surface in the HMG box, which exhibits strong evolutionary conservation, and has been studied through numerous NMR and X-ray crystallography studies [35–38]. Sox protein modifications that modulate DNA binding therefore represent a tractable target to disrupt/promote DNA interactions. However, it is notable those reported PTMs of Sox proteins which influence DNA binding lie outside of the HMG box, which suggests that it may not be directly accessible to modification (Fig. 3; Table 1) [39].

Protein phosphorylation adds a phosphate group to either a tyrosine, threonine or serine. The addition of negative charge to a protein can result in a distinct change in its biophysical properties. In Sertoli cells SRY is phosphorylated by PKA, at the N-terminal of its HMG box which positively regulates DNA-binding and results in inhibition of basal promoter activity located downstream of an SRY DNA-binding site concatemer [35]. This could be due to phosphorylation altering protein conformation of SRY which promotes binding to DNA. In lung squamous cell carcinoma, Sox2 is phosphorylated by PKGI at Thr116 (hs; mm Thr118) and this is necessary for occupancy at the HHAT promoter leading to promotion of the stem cell-like phenotype [40]. Sox2 Thr116 (hs; mm Thr118) resides between the HMG domain and a consensus nuclear localisation sequence in Sox2 indicating that phosphorylation may modulate HMG-DNA interaction or nuclear localisation [40]. As there were no apparent localisation defects, these data suggest that modulating DNA interactions around the HMG box increase the ability of Sox proteins to bind to DNA, which could possibly be due to the introduction of a conformational change which increases affinity to DNA and/or chromatin.

SUMOylation (small ubiquitin-like modifier) is an important PTM that often alters the activity of many different transcription factors when it is covalently attached to a lysine residue. This is analogous to ubiquitination, with a series of enzymatic reactions leading to attachment of these proteins to a target protein. SUMOylation is most commonly reported to play a role in repressing transcriptional activity. Sox2 is SUMOylated, and this can influence its transcriptional activity. An example is Lys247 of Sox2 (mm; Lys245) which under normal conditions binds to the Fgf4 enhancer but following conjugation of SUMO1 at Lys247 (mm; Lys245) there is reduced binding [41]. Sox2 SUMOylation therefore can negatively regulate transcription at key target genes through impairing of DNA binding (Fig. 4).
6. Perturbing SOX family transcriptional activity

A related mode of action for PTMs is to influence SOX protein-protein interactions. Protein partner changes can dramatically switch activation, repression or transcriptional specificity of targets (e.g., motif binding). Phosphorylation often acts as an anchor for protein-protein interactions (e.g., dimerisation) and therefore can stimulate recruitment of transcriptional coactivators/repressors (Fig. 4). Sox2 is phosphorylated at Thr118 (mm; hs Thr116) by Akt and this has been reported to enhance the transcriptional activation of Sox2 in mouse embryonic stem cells (ESCs) and also enhancing the activity of Sox2 in reprogramming of mouse embryonic fibroblasts to induced pluripotent stem cells [42]. Sox2 is also phosphorylated by Cyclin-dependent kinase (CDK) at Ser37 (hs; mm Ser39) and Ser251 (hs; mm Ser253) with proposed functional roles in reprogramming to pluripotency [43]. Ser37 (hs; mm Ser39) and Thr118 (mm; hs Thr116) are flanking the HMG box which could confer conformational changes and/or promote interaction with transcriptional co-regulators.

Another example of phosphorylation modulating transcriptional activity is the phosphorylation of Sox9 at Ser64 (hs/mm) and Ser181 (hs/mm) by PKA in response to BMP/TGF signalling, which results in its transcriptional activation, in turn driving Sox9 dependent changes like delamination and osteochondrogenic differentiation [44-47]. These amino acids lie near its dimerisation domain (Ser64) and HMG box (Ser181) which indicates that phosphorylation may modulate dimerisation of Sox9 and/or its interaction with DNA. Phosphorylation may therefore either alter the different dimers that Sox9 can make by recruiting different SoxE members (heterodimers vs. homodimers), preventing dimerisation, or modulating DNA interactions. In melanoma, Sox10 which is phosphorylated at Ser24 (hs/mm) and Thr240 (hs/mm) at sites which are predicted to be controlled by MAPK/CDK phosphorylation [48]. These sites are also highly conserved amongst SoxE family members suggesting a broad method of targeting these proteins in various different cancers [48]. Loss of these sites triggers an small increase in Sox10 transcriptional activity [48]. In all, SoxE family members have a wide range of phosphorylation sites that regulate their transcriptional activity by either increasing activity or changing activity. SoxE family members have been shown to be important in both maintenance of neural crest progenitors and ensuring their proper differentiation [49]. It could therefore be speculated that phosphorylation at the residues identified above could act as a TF switch that influences cell differentiation state. This could be exploited in a cancer therapeutic approach to influence the fate of cancer stem cells, such as driving terminal differentiation. Alterations to phosphatases might also influence SOX activity. Okadaic acid can broadly inhibiting serine/threonine phosphatases and results in an increase in Sox18 transcriptional activity. Sox18 transcriptional activity is reduced when prospective sites are mutated [50]. These sites are suggested to be downstream of either PKA or CK2 [50].

Methylation and acetylation result in the addition of a hydrophobic moiety to a protein, in the form of either a methyl group or acetyl group [51,52]. These PTMs have been extensively studied in the context of histone tail modifications. However, many proteins can be modified in this way [53]. Methylation has indeed been reported for Sox2 in ESCs, and is regulated by the coactivator-associated arginine methyltransferase 1 (CARM1). CARM1 mediates Sox2 transactivation by methylating Sox2 at Arg113 (hs; mm Arg115) resulting in enhanced oligomerization – possibly through the formation of dimers or larger protein complexes [54]. Interestingly, the chromatin-bound pool of Sox2 has a reduced methylation compared to unbound, suggesting that methylation may be important in loading and retaining Sox2 to transcriptional sites. Arg113 (hs; mm Arg115) flanks the HMG-domain of SOX2 which suggests that methylation may perturb DNA binding or that a region near the HMG is important in oligomerisation. CARM1 has also been shown to methylate Sox9 at multiple arginine residues near/ on its HMG box domain in chondrocytes. This modification disrupts Sox9 interaction with beta-catenin which increases Cyclin D1 expression and therefore drives cell cycle progression [55]. It is unclear if this is due to Sox9 repressing beta-catenin transcriptional activity through its interaction, or if the methylation drives Sox9 transcriptional activity.

In ESCs, SOX2 is SUMOylated by the SUMO-E3 ligase, Pias3, which results in the impairment of the interaction with Oct4 and downstream transcription.
disruption of key transcriptional targets, such as Nanog [56]. Furthermore, Sox6 sumoylation of either Lys404 (hs/mm) and Lys417 (hs/mm) perturbs its transcriptional activity [57]. Disruption of the SUMO modification site or its conjugating enzyme, Ubc9, result in an increase in transcriptional activity in both Sox2 and Sox6 [56,57]. Ubc9 has also been found to interact with Sox10 to drive its sumoylation at Lys55/357, which leads to repression of its transcriptional activity at 2 of its target genes, GJB1 and MITF (by altering how it interacts with its cofactors EGR2 and PAX3) [58]. Furthermore, SUMOylation of Sox10 is antagonised by predicted MAPK sites at Thr240 and/or Thr244 (hs/mm) however Lys55 (hs/mm) SUMOylation is required for SOX10 transcriptional activity [59]. Sox9 is SUMOylated at Lys61 (hs/mm), Lys253 (hs/mm), Lys398 (hs; mm Lys396) during chick development, within the neural crest progenitors during delamination. These Sox9 sites are required for its interaction with the zinc-finger-type transcription factor, Snail2, suggesting that SUMOylation is driving transcriptional activity [44–47,60–63]. Thus, while modification with SUMO most commonly reduces transcriptional activity/Promotes stabilisation [44–47,60–63], with regard to acetylation, Sox9 interacts with and is acetylated by KAT5 (Tip60) at Lys61 (hs/mm), Lys253 (hs/mm), Lys398 (hs; mm Lys396) during chick development, within the neural crest progenitors during delamination. These Sox9 sites are required for its interaction with the zinc-finger-type transcription factor, Snail2, suggesting that SUMOylation is driving transcriptional activity [44–47,60–63]. This SUMOylation of Sox9 is mediated by Sox9 phosphorylation (Ser181/Ser211 (hs/mm)) [44–47,60–63]. Thus, while modification with SUMO most commonly reduces transcriptional activity/Promotes transcriptional activity/Promotes stabilisation [44–47,60–63].

Table 1

<table>
<thead>
<tr>
<th>SOX Protein</th>
<th>Modification</th>
<th>Species identified in</th>
<th>Human Residue</th>
<th>Catalytic enzyme</th>
<th>PTM Effect</th>
<th>Citation</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOX2</td>
<td>Acetylation</td>
<td>Mouse</td>
<td>K35</td>
<td>Unknown</td>
<td>Unknown</td>
<td>[91]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Phosphorylation</td>
<td>Mouse/Human</td>
<td>S217</td>
<td>CDK</td>
<td>Enhances transcriptional activity</td>
<td>[43,98]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Acetylation</td>
<td>Mouse</td>
<td>K58</td>
<td>Unknown</td>
<td>Unknown</td>
<td>[91]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Acetylation</td>
<td>Mouse</td>
<td>K65</td>
<td>Unknown</td>
<td>Unknown</td>
<td>[91]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Acetylation</td>
<td>Mouse/Human</td>
<td>K73</td>
<td>p300/CBP</td>
<td>Promotes nuclear export</td>
<td>[91]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Acetylation</td>
<td>Mouse</td>
<td>K87</td>
<td>Unknown</td>
<td>Unknown</td>
<td>[91]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Acetylation</td>
<td>Mouse</td>
<td>K95</td>
<td>Unknown</td>
<td>Unknown</td>
<td>[91]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Acetylation</td>
<td>Mouse</td>
<td>K103</td>
<td>Unknown</td>
<td>Unknown</td>
<td>[91]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Acetylation</td>
<td>Mouse</td>
<td>K109</td>
<td>Unknown</td>
<td>Unknown</td>
<td>[91]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Methylation</td>
<td>Mouse</td>
<td>R111</td>
<td>CARM1</td>
<td>Enhances transcriptional activity</td>
<td>[30]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Acetylation</td>
<td>Mouse</td>
<td>K115</td>
<td>Unknown</td>
<td>Unknown</td>
<td>[91]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Methylation</td>
<td>Mouse</td>
<td>R117</td>
<td>SETD7</td>
<td>Promotes degradation</td>
<td>[73]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Phosphorylation</td>
<td>Human</td>
<td>T116</td>
<td>PKC</td>
<td>Required for promoter occupancy/Enhances transcriptional activity/Promotes stabilisation</td>
<td>[46,42]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Acetylation</td>
<td>Mouse</td>
<td>K121</td>
<td>Unknown</td>
<td>Unknown</td>
<td>[91]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Ubiquitination</td>
<td>Mouse</td>
<td>K121</td>
<td>Unknown</td>
<td>Promotes Degradation</td>
<td>[86]</td>
</tr>
<tr>
<td>SOX2</td>
<td>SUMOylation</td>
<td>Mouse</td>
<td>K245</td>
<td>PIAS, UBC9</td>
<td>Impairs DNA binding/Impairs Protein interactions/Reduces transcriptional activity</td>
<td>[41,56]</td>
</tr>
<tr>
<td>SOX2</td>
<td>Phosphorylation</td>
<td>Mouse/Human</td>
<td>S251</td>
<td>CDK1, MAPK1/3, Aurora Kinase A</td>
<td>Promotes SOX2 associated transcriptional programs</td>
<td>[43,79,98]</td>
</tr>
<tr>
<td>SOX4</td>
<td>Acetylation</td>
<td>Human</td>
<td>K95</td>
<td>KAT5</td>
<td>Chromatin Remodelling</td>
<td>[73]</td>
</tr>
<tr>
<td>SOX6</td>
<td>Phosphorylation</td>
<td>Mouse/Human</td>
<td>T119</td>
<td>CDK5</td>
<td>Promotes degradation</td>
<td>[67]</td>
</tr>
<tr>
<td>SOX6</td>
<td>SUMOylation</td>
<td>Human</td>
<td>K404</td>
<td>UBC9</td>
<td>Represses SOX6 transcriptional activity</td>
<td>[57]</td>
</tr>
<tr>
<td>SOX6</td>
<td>SUMOylation</td>
<td>Human</td>
<td>K417</td>
<td>UBC9</td>
<td>Enhances transcriptional activity</td>
<td>[57]</td>
</tr>
<tr>
<td>SOX9</td>
<td>Acetylation</td>
<td>Human</td>
<td>K61</td>
<td>KAT5</td>
<td>Enhances transcriptional activity</td>
<td>[65]</td>
</tr>
<tr>
<td>SOX9</td>
<td>SUMOylation</td>
<td>Chicken</td>
<td>K61</td>
<td>Unknown</td>
<td>Unknown</td>
<td>[46]</td>
</tr>
<tr>
<td>SOX9</td>
<td>Phosphorylation</td>
<td>Mouse/Human</td>
<td>S64</td>
<td>Upstream: BMP, TGF Kinase: PKA</td>
<td>Enhances transcriptional activation</td>
<td>[44–47,63,64]</td>
</tr>
<tr>
<td>SOX9</td>
<td>Methylation</td>
<td>Mouse</td>
<td>R74</td>
<td>CARM1/PRMT4</td>
<td>Possibly enhances transcriptional activity</td>
<td>[55]</td>
</tr>
<tr>
<td>SOX9</td>
<td>Methylation</td>
<td>Mouse</td>
<td>R152</td>
<td>CARM1/PRMT4</td>
<td>[55]</td>
<td></td>
</tr>
<tr>
<td>SOX9</td>
<td>Methylation</td>
<td>Mouse</td>
<td>R177</td>
<td>CARM1/PRMT4</td>
<td>[55]</td>
<td></td>
</tr>
<tr>
<td>SOX9</td>
<td>Methylation</td>
<td>Mouse</td>
<td>R179</td>
<td>CARM1/PRMT4</td>
<td>[55]</td>
<td></td>
</tr>
<tr>
<td>SOX9</td>
<td>Phosphorylation</td>
<td>Mouse/Human</td>
<td>S211</td>
<td>PKA, p38, SMAD</td>
<td>[45,64]</td>
<td></td>
</tr>
<tr>
<td>SOX9</td>
<td>Phosphorylation</td>
<td>Human</td>
<td>T236</td>
<td>Upstream: PI3K/akt/mTOR</td>
<td>Promotes degradation</td>
<td>[88]</td>
</tr>
<tr>
<td>SOX9</td>
<td>Acetylation</td>
<td>Human</td>
<td>K253</td>
<td>KAT5</td>
<td>Enhances transcriptional activity</td>
<td>[65]</td>
</tr>
<tr>
<td>SOX9</td>
<td>SUMOylation</td>
<td>Chicken</td>
<td>K253</td>
<td>Unknown</td>
<td>[46]</td>
<td></td>
</tr>
<tr>
<td>SOX9</td>
<td>SUMOylation</td>
<td>Chicken</td>
<td>K398</td>
<td>Unknown</td>
<td>[46]</td>
<td></td>
</tr>
<tr>
<td>SOX9</td>
<td>Acetylation</td>
<td>Human</td>
<td>K398</td>
<td>KAT5</td>
<td>[65]</td>
<td></td>
</tr>
<tr>
<td>SOX10</td>
<td>Phosphorylation</td>
<td>Mouse/Human</td>
<td>S24</td>
<td>Predicted: CDK, MAPK</td>
<td>Represses transcriptional activity/Promotes degradation</td>
<td>[48]</td>
</tr>
<tr>
<td>SOX10</td>
<td>Phosphorylation</td>
<td>Mouse/Human</td>
<td>S45</td>
<td>Predicted: CDK, MAPK</td>
<td>Slight increase in activity</td>
<td>[48]</td>
</tr>
<tr>
<td>SOX10</td>
<td>Phosphorylation</td>
<td>Human</td>
<td>S224</td>
<td>Ubc9</td>
<td>Represses transcriptional activity</td>
<td>[58]</td>
</tr>
<tr>
<td>SOX10</td>
<td>Phosphorylation</td>
<td>Human</td>
<td>S232</td>
<td>Unknown</td>
<td>[48]</td>
<td></td>
</tr>
<tr>
<td>SOX10</td>
<td>Phosphorylation</td>
<td>Human</td>
<td>T240</td>
<td>CDK, MAPK</td>
<td>Represses transcriptional activity</td>
<td>[48]</td>
</tr>
<tr>
<td>SOX10</td>
<td>Phosphorylation</td>
<td>Human</td>
<td>T244</td>
<td>Unknown</td>
<td>[48]</td>
<td></td>
</tr>
<tr>
<td>SOX10</td>
<td>SUMOylation</td>
<td>Human</td>
<td>K246</td>
<td>Unknown</td>
<td>[58]</td>
<td></td>
</tr>
<tr>
<td>SOX10</td>
<td>SUMOylation</td>
<td>Human</td>
<td>K357</td>
<td>Ubc9</td>
<td>Represses transcriptional activity</td>
<td>[58]</td>
</tr>
<tr>
<td>SOX11</td>
<td>Phosphorylation</td>
<td>Mouse</td>
<td>S30</td>
<td>Unknown</td>
<td>Promotes nuclear localisation</td>
<td>[92]</td>
</tr>
<tr>
<td>SOX11</td>
<td>Phosphorylation</td>
<td>Mouse</td>
<td>S133</td>
<td>PKA</td>
<td>Fine-tunes transcriptional activity</td>
<td>[99]</td>
</tr>
<tr>
<td>SOX11</td>
<td>Phosphorylation</td>
<td>Mouse/K136</td>
<td>p300</td>
<td>Promotes nuclear import</td>
<td>[90]</td>
<td></td>
</tr>
</tbody>
</table>

**Table 1**

Table of Sox protein post translational modifications.
potential switch between acetylation and SUMOylation [65]. This modification increases Sox9 transcriptional activity. It would therefore be interesting to examine how these two modifications interact and how acetylation affects Snail2 interaction and how SUMOylation affects KAT5 interaction.

Altogether the above studies indicate that targeting the upstream enzymes that modulate (add/remove) PTMs on specific Sox protein transcriptional activity would have dramatic effects on Sox protein activity and function – although in complex and difficult to predict ways.

7. Disrupting pioneer activity

Eukaryotic genomes are organised into distinct chromatin territories – either compacted or more open and accessible – that stabilise the existing patterns of gene expression, helping to preserve cell type identity and limit inappropriate cell fate conversions. It is therefore critical to understand how transcription factors such as SOX members interact with distinct forms of chromatin. It has generally been viewed that transcription factors would bind most strongly to naked DNA, and become more restricted in their binding once the DNA becomes wrapped around histones, forming the nucleosome. However, it is becoming increasingly clear that certain transcription factors can strongly interact with nucleosome bound DNA. For example, SOX2 binds nucleosomes more strongly than naked DNA [66]. Transcription factors with these properties can therefore access closed chromatin and target silent genes for subsequent reactivation; they have been termed ‘pioneer’ factors [67]. This might be a key biochemical feature underpinning their importance as master regulators of cell type and as reprogramming factors [16,68]. Related to this, recent studies have suggested that binding to nucleosomes may impart the ability of pioneer factors to bind mitotic chromatin, acting as ‘book-marking’ proteins [69]. This mitotic bookmarking ability has been found to be more prevalent than previously thought and has been reported for Sox2 in ES cells [70]. The mitotic bookmarking function play a crucial role for maintaining cell identity through the cell cycle stages (reviewed in: Ref. [71]), which have direct implications on cycling and quiescent cancer cells. The role of PTM of Sox factors in regulating their pioneer activities is currently unknown yet could provide a key regulatory step.

Although not a Sox factor, HMG-14, which shares features with Sox proteins, is acetylated by p300 which weakens its interaction with nucleosomes [72]. We would speculate that large modifications like SUMOylation/ubiquitylation would disrupt the intricate chromatin-transcription factor interactions; however, phosphorylation, methylation, and acetylation would be harder to predict. Mechanistic insights have been made by studies of how Sox4 orchestrates chromatin remodelling during myoblast differentiation. Sox4, a SoxC member, interacts with and is acetylated by the acetyltransferase, KAT5, at Lys95 (hs/mm). This facilitates Sox4 recruitment to DNA and through the KAT5 chromodomain aids with chromatin remodelling [73]. This highlights that even small PTMs can modulate Sox family pioneer activity (Fig. 4).

8. Degrading SOX family members

Sox protein levels are tightly controlled to maintain cellular homeostasis. Sox levels are modulated throughout the cell cycle, and transcriptional regulation is in part achieved by varying steady-state protein levels. Proteins can be downregulated through extinguishing transcription, but also by post-translational control via protein degradation pathways. The most studied protein degradation is the ubiquitination system, although other PTMs can modulate this, such as phosphorylation [74]. Regulation of protein degradation pathways is therefore a clear route to perturbing the promiscuous activity of Sox factors in cancer (Fig. 4).

PTMs are not mutually exclusive, and an example of how they cooperate or antagonise one another, is the interplay between methylation, ubiquitination and phosphorylation on Sox2. In mouse ESCs, Sox2 protein expression is regulated by a novel methylation/phosphorylation switch. Setd7 efficiently monomethylates Sox2 at Lys119 (ms; hs Lys117). This methylation controls Sox2 protein stability by recruiting the ubiquitin ligase WWP2, whose catalytic HECT domain binds to the methylated lysine which in turn ubiquitylates Sox2 which results in its degradation [75]. In contrast, Akt1 phosphorylates Sox2 at Thr118 (mm; hs Thr116) which antagonises Lys119 (mm; hs Thr117) methylation and prevents subsequent degradation [76]. Additionally, Sox2 phosphorylation at Thr116 (hs; ms Thr118) by AKT antagonises degradation by the ubiquitin ligase UBR5 by preventing ubiquitination at Lys115 (hs; mm Lys117) [76]. It has been suggested that SOX phosphor-Thr118 (mm; hs Thr116) lies downstream of IGF-1 in a novel RIT/ Akt/ Sox2 axis [77]. Phosphorylation of SOX2 Ser251 (hs; mm Ser253) by ERK1/2 is also reported to promote autophagic degradation in nasopharyngeal carcinoma stem cells [78]. Mitotic SOX2 Ser251 (hs; mm Ser253) phosphorylation is also reported to be catalysed by Aurora A which maintains that a stem cell-like state [79]. These data demonstrate the importance of Sox factor protein stability in regulating cell fate.

The role of protein ubiquitination in regulating Sox factor stability is also exemplified in the stability of SOX2 during neural stem cell differentiation. During neural differentiation, the decrease in SOX2 protein expression is directly correlated to the expression of the deubiquitinating enzyme, OTUD7B and inversely to the reciprocal ubiquitin ligase complex, CUL4A/ HECT-COP1 [80]. Sox2 directly interacts with the substrate adaptor, COP1 which results in its polyubiquitination on multiple Lysine residues on Sox2, whereas OTUD7B deubiquitates Sox2 [80]. This modification is distinct from the WWP2 turnover of Sox2 which indicates that there may be differential regulation of Sox proteins between cell types. The CUL4A complexes are critical in regulating cell cycle machinery and indicates that Sox2 may have a novel role in the cell cycle [81]. Ubiquitin can form a polymer chain at any of its seven lysine residues which regulate, K11 linkages only accounts for a small percentage the total ubiquitination events in normal mammalian cells [82]. K11 is associated with proteasomal degradation of cell cycle components through the anaphase-promoting complex (APC) [83,84]. In addition, APC has been found to regulate neuronal morphogenesis and differentiation [85]. The generation of K11 linked chains are almost specifically driven by the priming E2, Ube2s, which has been identified as critical for maintaining pluripotency [86]. Interestingly, Sox2 is K11 ubiquitinated at Lys123 (mm; hs Lys121), thus marking it for degradation and contributes to Sox2-controlled differentiation to neuroectoderm [86]. This suggests that Sox2 is degraded at specific cell cycle stages to allow differentiation and could be manipulated in order to enforce differentiation of cancer stem cells.

Phosphorylation of proteins at specific residues can alter interactions with the degradation machinery: a phoso-degron. Sox6 is expressed in differentiating neurons with its expression gradually decreases through development. Sox6 is phosphorylated a phospho-degron at Thr119 (hs/mm) by Cdk5 which regulates Sox6 steady state protein levels in order to coordinate the proper differentiation into a post-mitotic state neuron [87]. Another example of a phoso-degron is on Sox9. Sox9 is phosphorylated by GSK3 kinase at Thr236 (hs/mm), FBW7 recognises a conserved degron surrounding this site which is degraded by the SCFβTrCP complex [88]. This was shown to be negatively regulated by a PI3K/AKT/mTOR signalling axis. As shown in Fig. 1, Sox9 is highly expressed in medulloblastoma; in cases where FBW7 is dysregulated, Sox9 protein is elevated [88]. Inhibition of PI3K/AKT/mTOR signalling destabilises Sox9 which renders medulloblastoma cells sensitive to cytostatic treatment [88]. Interestingly, this residue and motif is conserved amongst all SoxE family members which suggest that there may be a unifying approach to targeting cancers where SoxE family members are overexpressed (Fig. 1). SOX10, which is highly expressed in melanoma tumours, was identified to be
phosphorylated at Ser24 (hs/mm). This site is predicted to be a MAPK/CDK substrate motif and mutation of this resulted in an increase in stability of SOX10 suggesting the presence of a phosphodegron [48].

These findings further the understanding of Sox10 protein levels and provides possibly novel targets for more effective combinatorial therapeutics. Modulation of the stability of Sox proteins may provide a way to compensate against the effects of oncogenic or SOX2 genomic amplifications observed in cancers. Therefore, targeting the pathways upstream with activators or agonists may provide a unique way to decrease Sox expression.

9. Mediating SOX nuclear localisation

Within the Sox HMG domain there is a conserved region which is a predicted to be a nuclear localisation signal (Reviewed in: Ref. [89]). Disruption of Sox factor localisation (less nuclear) has been shown upon perturbation of the acetylation of SRY by p300 at Lys136 (hs; ms not conserved) where this residue increases its interaction with importin-beta [90]. This is reversed by HDAC3. These data suggest that SRY acetylation may play an important regulatory role. Acetylation by p300 can also promote the export of other Sox factors. SOX2 is acetylated at Lys75 (mm. hs Lys73), within its HMG box, which disrupts its nuclear localisation and promotes nuclear export [91]. Disruption of this acetylation promotes SOX2 nuclear localisation and maintains its target gene expression. Therefore, p300 represents an interesting target for regulating the localisation of Sox proteins that are overexpressed in cancer (Fig. 4).

Sox11 is transiently active during neurogenesis which ensures precise execution of the neurogenic program. Sox11 phosphorylation at Ser30 (hs/mm), a residue N-terminal of the HMG box, promotes nuclear localisation [92]. The upstream kinases for this PTM remain unclear and could represent an interesting and druggable target to regulate Sox11 localisation.

10. Future perspectives

This review has summarised the numerous roles of PTMs that influence Sox proteins. There is a wealth of possibilities to influence SOX activity via modulation of PTMs. SOX PTMs that are at the core of controlling “stemness” can act as molecular switches for various cancer types. It is therefore important to understand how to target these using either small molecules, gene therapies or immunotherapies. The therapeutic exploitation of PTMs other than phosphorylation is still in its infancy. Phosphorylation, which is the most well studied PTM, led to 38 phosphorylation events which are highly liable or the recently identified cancer bio-030617-050400 annurev-cancerbio-030617-050400.

References


